Despite the remarkable advances in solid organ transplantation reflected by improved patient and graft survival rates, the treatment and management of solid organ transplant recipients remains a complex area of modern medicine. Organ transplant recipients are required to take life-long immunosuppressive medication to prevent their own immune systems from rejecting the donor organ (allograft). While current standard of care is very effective in the prevention and treatment of acute rejection, chronic rejection remains a high unmet medical need and is responsible for most cases of allograft failure.
Hematopoietic stem cell transplantation (HCT) is a potentially curative treatment option for patients with malignant or non-malignant hematologic diseases. Acute graft-versus-host disease (GvHD) is a serious condition that arises as a complication in recipients of HCT from allogeneic donors. GvHD is a leading cause of mortality and morbidity in allogeneic HCT. Currently, few therapeutic options exist for the prevention of GvHD and all patients undergoing HCT typically receive immunosuppressive medications. These agents also increase the risk of infection and/or contribute to increases in relapse mortality due to enhanced immunosuppression. As such, there is a significant medical need to develop effective, less toxic preventative therapies for acute GvHD. We are currently investigating the potential of our plasma derived product Alpha-1 Antitrypsin (AAT) for the prevention of acute GvHD in patients receiving an allogenic HCT.
Clazakizumab, our anti-interleukin-6 (IL-6) monoclonal antibody, is currently being investigated in a Phase 3 clinical trial (IMAGINE) for the potential treatment of chronic active antibody-mediated rejection.